.png)
Key Messages:
Antimicrobial Resistance is a growing health concern, both globally and in Denmark, and is associated with an estimated 2,500 deaths in Denmark each year.
The pipeline of new antimicrobials has grown increasingly thin and is inadequate to provide the vital new medicines that are needed to treat an increasing number of drug-resistant infections.
Through working towards establishing a “pull incentive” scheme, Denmark, alongside other countries in the EU and globally, can play an important role in reinvigorating the antimicrobial pipeline and ensuring patients have access to adequate treatments.
We model that a scheme aimed at incentivising the development of and securing access to 18 new antimicrobials over 30 years would:
Save 350 lives, generate €300 million in benefits and give a Return on Investment of 3.5:1 over a 10 year period.
Save 6,700 lives, generate €4.7 billion in benefits and give a Return on Investment of 16.5:1 over a 30 year period.
Such a scheme would cost Denmark an estimated €33 million per drug over a 10 year period, representing its “fair share” of a G7 + European Union pull incentive.
